Signaling molecule calcitonin gene-related peptide (CGRP) induces migraine attacks and anti-CGRP medications abort and prevent migraine attacks. Whether CGRP provokes cluster headache attacks is unknown.
graine and cluster headache share some features like response to triptans, 7,8 attack induction by glyceryl trinitrate, 9, 10 and elevated plasma levels of CGRP. 11, 12 Elucidating the role of CGRP in cluster headache attack induction will provide novel insights to mechanisms underlying the disease. A role of CGRP in attack generation would provide novel opportunities for targeted treatment of this severely disabling disease. We hypothesized intravenous infusion of CGRP would provoke cluster headache attacks in episodic cluster headache during the active phase but not during the remission phase. We also hypothesized CGRP would provoke cluster headache attacks in patients with chronic cluster headache. To test these hypotheses, we conducted a randomized, double-blind, placebo-controlled, 2-way crossover study.
Methods

Study Design and Participants
We recruited participants from the Danish Headache Center outpatient clinic between December 2015 and April 2017. Participants aged 18 to 65 years were eligible when having a verified diagnosis of episodic or chronic cluster headache according to the International Classification of Headache Disorders.
2 Patients were defined as having active-phase episodic cluster headache when experiencing usual attacks within the last 30 days, remission-phase episodic cluster headache when attack-free for a minimum of 30 days, or chronic cluster headache when no more than 30 consecutive attack-free days during the previous 12 months or longer. Cluster headache preventive medications were allowed. Use of safe contraceptive methods if a woman of childbearing potential was required. Exclusion criteria were any history of other primary headache (except episodic tensiontype headache <5 days per month), pregnant or nursing women, cardiovascular or cerebrovascular disease, psychiatric disease, or drug misuse. Enrollment was done at Righospitalet Glostrup. The Regional Health Research Ethics Committee of the Capital Region approved the study (H-15006836). All participants gave written consent after receiving detailed oral and written information. The study was conducted at the Danish Headache Center in accordance with the Declaration of Helsinki, 13 with later revisions. The study was registered at ClinicalTrials.gov (identifier NCT02466334) and approved by the Danish Data Protection Agency. The full trial protocol is available in Supplement 1.
Experimental Design
We randomly allocated participants to receive continuous intravenous infusion of 1.5 μg/min of CGRP or placebo during 20 minutes on 2 study days separated by at least 7 days. Calcitonin gene-related peptide dose was identical to that in migraine provocation studies. 14,15 Participants were informed that CGRP might induce headache, but timing and type of headache, including if it would mimic their usual cluster headache attacks, was not discussed. No study individuals had previously participated in provocation studies. All procedures were performed with individuals in supine position, a venous catheter inserted into an antecubital vein, and CGRP infused over 20 minutes using a time-and volume-controlled infusion pump. For details on balanced allocation, blinding, and randomization, see eAppendix in Supplement 2. All patients arrived nonfasting during the daytime. On study day 1, a brief medical and neurological examination and 12-lead electrocardiogram was performed before experiment start. Patients with episodic cluster headache in active phase and patients with chronic cluster headache were at least 3 hours attack-free. All patients with remission-phase episodic cluster headache were, apart from being cluster headache attackfree for a minimum of 30 days, also free of any other type of headache for at least 8 hours at infusion start. Pregnancy tests were completed in women before each infusion. After 15 minutes of rest, baseline (10 minutes before infusion start and at the time of infusion start) headache intensity and vital signs were measured.
Headache Intensity and Questionnaire
If headache of any type occurred, headache intensity was recorded. This was done at baseline (10 minutes before infusion start and at the time of infusion start) and after the intervention every 10 minutes until 1.5 hours (90 minutes after infusion start) on an 11-point numerical scale from 0 to 10, with 0 representing no headache; 1, a very mild headache (including sensations of pressing, throbbing, or otherwise altered sensation in the head not associated with pain); 5, headache of moderate intensity; and 10, the worst headache imaginable. If participants reported a cluster headache attack at 70 minutes after infusion start and later, we extended the recording period with at least 30 minutes to ensure complete capture of attack development. Participants were asked to characterize any headache occurring during the observation period as resembling usual cluster headache or not. Additionally, headache characteristics (throbbing, stabbing, pressing), headache localization, and intake of rescue medication including intake time and dosage were recorded.
Cluster Headache-like Attack Criteria
The applied criteria for an experimentally provoked clusterlike attack in the present study are shown in the Box (see eAppendix in Supplement 2 for background on criteria). Based on previous cluster headache provocation studies, 10,16,17 we defined attacks as provocation-related when occurring 0 to 90 minutes after infusion start. On study day 1 before infusion, we asked participants to retrospectively estimate their attack frequency the preceding 30 days. For measured vital signs, nonheadache, and CAS, see eAppendix in Supplement 2.
Statistical Analyses
Headache intensity scores are presented as medians and time to onset of cluster headache-like attacks, and autonomic symptoms after CGRP infusion are presented as medians, interquartiles, and range. Heart rate and mean arterial pressure data are presented as median values. Sample size was chosen based on previous similar migraine studies showing migraine attack induction in 60% to 70% of patients after administration of CGRP and 20% after placebo at 5% significance with 80% power. 5 We calculated that 15 participants in each group would be sufficient to show a difference between 2 experimental days (eAppendix in Supplement 2). The primary end points were difference in incidence of cluster headache-like attacks, difference in area under the curve (AUC) for headache intensity scores (0 to 90 minutes), and difference in time to peak headache between CGRP and placebo in the 3 groups. Secondary end points were differences in AUC for mean arterial pressure and heart rate during the in-hospital phase (0 to 90 minutes). Incidence of clusterlike attacks and CAS in each group of patients was analyzed as categorical data using McNemar test. We calculated AUC according to the trapezium rule to obtain a summary measure. Area under the curve from 0 to 90 minutes for headache scores, mean arterial pressure, and heart rate were compared using Wilcoxon signed-rank test. Incidence of attacks and AUC from 0 to 90 minutes of headache are presented with means and 95% CI. We tested for carryover effects of randomization to CGRP vs placebo on study day 1 with Fisher exact test. Difference in time to peak headache between CGRP and placebo was not calculated owing to a total of only 1 cluster headache attack occurring with placebo. All analyses were performed with GraphPad Prism Statistics, version 7, for Windows (GraphPad Software, Inc). We made no adjustment for multiple analyses. Thus, the level of significance at .05 was accepted for each comparison.
Results
Of 37 recruited participants, 32 (86.5%) were included in the final analysis (27 men [84.4%] and 5 women [15.6%]) ( Figure 1 ).
Box. Cluster Headache-like Attack Criteria
The following criteria were used for an experimentally induced clusterlike attack. Clusterlike headache attack must fulfill either: a Cerebral autonomic symptoms, restlessness, and immediate treatment is reported from 0 to 90 minutes after 20 minutes of intravenous infusion of calcitonin CGRP (1.5 μg/min) or placebo.
b Patients rated the intensity of their headache on an 11-point scale, with 0 indicating no headache; 1, a very mild headache (including a sensation of pressing or throbbing or otherwise altered sensation in the head not associated with pain); 5, headache of moderate intensity; and 10, the worst headache imaginable.
c Clusterlike attack is defined according to criteria described in the Methods section.
d Therapy effect: more than 50% reduction in pain intensity over 2 hours.
e Patient developed a clusterlike attack on study days. 
1193
The mean (SD) age was 36 (10.7) (range, 19-60 years) years, and the mean weight was 78 kg (range, 53-100 kg). Enrollment ended before reaching 45 participants owing to recruitment difficulties. Nine patients (28.1%) with episodic cluster headache were included during active phases and 9 (28.1%) were included during remission. Fourteen patients (43.8%) had chronic cluster headache. Detailed descriptions of usual attacks, attack treatment, preventive medication, and study day information are listed in the Table. For analysis of carryover effect and details on intake of preventive medication, patients in active disease phase, and vital signs, see eAppendix in Supplement 2.
Patients With Active-Phase Episodic Cluster Headache
During the 90-minute in-hospital phase, 8 of 9 patients with active-phase episodic cluster headache reported a clusterlike attack after CGRP (mean, 89%; 95% CI, 63%-100%) compared with 1 of 9 after placebo (mean, 11%; 95% CI, 0%-37%) (P = .05) (Table) . All except 1 attack occurred on the patient's usual side, and no bilateral attacks occurred (Table) . During CGRP-induced attacks, all 8 patients with episodic cluster headache in active phase experienced CAS and/or agitation (Table) . The mean AUC from 0 to 90 minutes for CGRP was 1.903 (95% CI, 0.842-2.965), and the mean AUC from 0 to 90 minutes for placebo was 0.343 (95% CI, 0-0.867) (P =.04)( Figure 2 ).
Patients With Remission-Phase Episodic Cluster Headache
During the 90-minute in-hospital phase, no patients with remission-phase episodic cluster headache reported clusterlike attacks after CGRP or placebo (Table) . In addition, no patients with remission-phase episodic cluster headache reported attacks the following 24 hours. The mean AUC from 0 to 90 minutes for CGRP was 0.187 (95% CI, 0-0.571), and the mean AUC from 0 to 90 minutes for placebo was 0.019 (95% CI, 0-0.062) (P > .99) (Figure 2 ). The eAppendix in Supplement 2 includes a description of headache in the 2 patients excluded for coexisting migraine.
Patients With Chronic Cluster Headache
During the 90-minute in-hospital phase, 7 of 14 patients with chronic cluster headache reported a clusterlike attack after CGRP (mean, 50%; 95% CI, 20%-80%) compared with none after placebo (mean, 0; 95% CI, 0%) (P = .02) (Table) . All attacks occurred on the patient's usual attack side, and no patients reported bilateral attacks (Table) . During CGRP-induced attacks, 6 of 7 patients with chronic cluster headache experienced CAS (Table) . The median time to onset of attack, autonomic symptoms, restlessness, and intake of medication are shown in Figure 3 .
In the 30 days before study day 1, the 7 patients who did report a clusterlike attack after CGRP reported a median attack frequency of 33. The 7 patients who did not report attack after CGRP had a median attack frequency of 7.5 ( Figure 4) . The mean AUC from 0 to 90 minutes for CGRP was 1.214 (95% CI, 0.395-2.033), and the mean AUC from 0 to 90 minutes for placebo was 0.036 (95% CI, 0-0.114) (P = .01) (Figure 2 ).
Discussion
A key novel finding of the present study was that CGRP provoked cluster headache attacks only in patients with episodic cluster headache during the active phase and not in patients in remission. Another important finding was the influence that attack frequency (periodicity) had on incidence of CGRPinduced attacks in patients with chronic cluster headache.
Overall, our findings suggest that (1) CGRP plays a pivotal role in initiation of a single cluster headache attack and (2) that CGRP induces cluster attacks may suggest a possible clinical efficacy of pharmacological interventions that block the effects of CGRP (eg, specific monoclonal antibodies). In episodic and chronic cluster headache, monoclonal CGRP antibodies are currently being investigated in phase III studies as preventive treatment with study completion expected in 2018. Medians, interquartiles, and ranges from 0 to 90 minutes after 20-minute intravenous infusion of calcitonin gene-related peptide (1.5 μg/min) are reported. The blue arrow indicates the duration of infusion. CCH indicates chronic cluster headache, ECHA, episodic cluster headache in active phase.
Research Original Investigation Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks
Our findings raised an important question of how infusion of CGRP induces cluster headache attacks in active disease phase (ie, patients with episodic cluster headache in active phase and patients with chronic cluster headache). Studies in patients with cluster headache reported elevated ictal plasma levels of CGRP, which normalized after oxygen inhalation and subcutaneous sumatriptan injection.
11 Interestingly, plasma CGRP is also elevated in patients during active phase compared with patients during remission.
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Calcitonin gene-related peptide is one of the most powerful vasodilators known, and CGRP immunoreactive nerves innervate human cranial arteries. 19 The intracellular signal- which has been suggested as the possible site of action for the CGRP receptor antagonists in migraine treatment. 26 Third, neurons in sphenopalatine ganglion express CGRP and its receptor components. 22 Efferent outflow from sphenopalatine ganglia is suggested as initiating mechanism of cluster headache attacks, and on-demand sphenopalatine ganglia stimulation is an effective novel therapy for individuals with cluster headache with dual effects, acute pain relief, and attack prevention. 28 Interestingly, in the present study, the median time to onset of parasympathetic symptoms preceded median onset of head pain. These data indicate that CGRP may induce parasympathetic outflow and trigger cluster headache attacks. Collectively, these data suggest that mechanisms behind CGRP-induced cluster headache attacks likely The median is indicated by orange lines, and individuals are indicated by blue lines. Headache intensity was rated on an 11-point numerical scale from 0 to 10 for 9 patients with episodic cluster headache in active phase, 14 patients with chronic cluster headache, and 9 patients with episodic cluster headache in remission from 0 to 90 minutes after 20-minute intravenous infusion of calcitonin gene-related peptide (CGRP) (1.5 μg/min) and placebo. In episodic active phase, the area under the curve (AUC) 0 to 90 minutes of headache intensity after CGRP was larger than placebo (P = .04), the median peak attack pain intensity after CGRP was 3.5 (range, 1-10), mean of AUC from 0 to 90 minutes for CGRP was 1.903 (95% CI, 0.842-2.965), and the mean AUC from 0 to 90 minutes of placebo was 0.343 (95% CI, 0-0.867). In chronic cluster headache, the AUC from 0 to 90 minutes of headache intensity after CGRP was larger than placebo (P = .01), the mean of AUC from 0 to 90 minutes for CGRP was 1.214 (95% CI, 0.395-2.033), and mean AUC from 0 to 90 minutes of placebo was 0.036 (95% CI, 0-0.114). In episodic remission phase there was no difference in the AUC from 0 to 90 minutes of headache intensity between CGRP and placebo (P > .99, mean of AUC from 0 to 90 minutes for CGRP was 0.187 (95% CI, 0-0.571), and mean AUC from 0 to 90 minutes of placebo was 0.019 (95% CI, 0-0.062). Usual attacks happened 24 hours after completing study days 1 and 2. Data are reported 0 to 90 minutes after 20-minute intravenous infusion of calcitonin gene-related peptide (CGRP) (1.5 μg/min) and placebo. brain stimulation has no effect on acute attacks but prevents cluster headache attacks after a lag time of days to weeks. This suggests that simple direct neuronal inhibition in the hypothalamus is not responsible for the success of deep brain stimulation. 35 Rather, the hypothalamus may modulate the system lowering the provocability threshold down to allowing a peripheral trigger to set off attacks.
In the present study, CGRP infusion induced cluster headache attacks in 7 (5 men and 2 women) of 14 (11 men and 3 women) patients with chronic cluster headache. Intake of preventive medications was similar in those who developed attack (5 of 7) and those who did not (4 of 7). Thus, intake of preventive medication seems insufficient in explaining provocability in patients with chronic cluster headache. Interestingly, exploratory analyses showed that in the month before provocation, patients with chronic cluster headache who experienced attacks after CGRP reported a median of 33 attacks, contrasting 7.5 attacks in patients who were not triggered by CGRP. This could indicate (1) those with fewer attacks may benefit more from their preventive medication than those with more attacks, possibly explaining their insusceptibility to CGRP provocation; (2) those with fewer attacks may have higher thresholds for CGRP-induced attacks; and (3) high attack frequency in those who developed attack after CGRP may indicate increased disease activity and low threshold for triggering because of possible periodicity in chronic cluster headache. In support, circannual periodicity of chronic cluster headache has been suggested in some patients with chronic cluster headache. 36 Participants were asked about attack frequency in the month before provocation before infusion start on study day 1. Although participants at this time were unaware of their provocability status, we cannot rule out recall bias.
Limitations
We acknowledge some of the limitations of the present study. The differences in CGRP-induced attacks in patients with chronic cluster headache based on usual attack frequency should be interpreted cautiously because baseline (1 month before experimental day 1) attack frequency was collected retrospectively. Ideally, data should have been collected during 1-month run-in period by electronic diary. Furthermore, patients were allowed to use preventive medication, which could have influenced the threshold to induce cluster headache attacks. However, we found similar numbers of patients using preventive medication in patients with chronic cluster headaches who developed attacks and in patients with chronic cluster headaches who did not develop attacks. One might argue that some provoked attacks were mild to moderate in pain intensity. However, patients may report variability in pain intensity during spontaneous attacks, which is noted in the International Classification of Headache Disorders, 3rd edition, cluster headache criteria.
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Conclusions
We demonstrated that CGRP provokes cluster headache attacks in patients with cluster headache exclusively during active phase in episodic cluster headache and in chronic cluster headache. We hypothesize that this difference hails from the hypothalamus modulating the provocability threshold of the system allowing a peripheral trigger to set off attacks. Our results also cautiously suggest efficacy of CGRP antagonism in the treatment of cluster headache and current phase III trials elucidating this 18 will emerge in coming years. 
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The participant is given a questionnaire for registration at home of any headache and other 235 symptoms in the following 12 hours. If the subject develops a cluster headache attack during the 236 trial, treatment will be offered in the form of oxygen or attack medicine Sumatriptan injection 6 mg 237 In order to validate the assay, independently of the experiment, blood samples of 15 healthy 275 subjects will be taken. In these blood samples, serum concentrations of VIP, PACAP38, S100B, 276 NSE and CGRP are also measured. 
Methods
Balanced allocation, blinding and randomization
Allocation was done on study day one and participants received the opposite on day two. Allocation was balanced to ensure approximately even numbers of participants receiving CGRP first and placebo last or vice versa. The regional central pharmacy prepared and randomized the experimental drug in a balanced fashion. CGRP and placebo vials were completely identical and all participants and study investigators were blinded to the content of the vials. The randomization code remained in the hospital during the study and was unavailable to investigators until study completion.
Cluster headache-like attack criteria
Experimentally provoked cluster headache by pharmacological substances is not spontaneous and therefore cannot fulfil strict IHS cluster headache attack criteria. The following facts are important in defining criteria for induced cluster-like attacks. First, the cluster-like attacks reported are triggered by a pharmacological substance and can therefore not be spontaneous even if phenotypically similar to spontaneous attacks. Secondly, for ethical reasons we cannot deny patients attack treatment while awaiting pain intensity to become severe
Cephalic autonomic symptoms and non-headache symptoms
We recorded the following cephalic autonomic symptoms typical for cluster headache; conjunctival injection, lacrimation, rhinorrhea, nasal congestion, eyelid edema, facial sweating, ptosis and miosis.
In addition, we recorded a feeling of inner restlessness.
Vital signs
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We measured mean arterial blood pressure (MAP) and heart rate using an auto-inflatable cuff (Microlife, Widnau, Switzerland) every 10 min from T-10 until T90 and monitored ECG (Cardiofax V Nihon Kohden, Tokyo, Japan) continuously during the same time interval.
Statistical analysis
We performed the following calculation (alpha multiplier 1.96, beta multiplier 0.842): 
Results
Because five subjects were excluded form final analyses the balanced allocation resulted in the following: 18 participants received CGRP on study day one and 14 received placebo on study day one. We found no carry over effect randomization to CGRP on study day one vs placebo on study day 1 on (p = 1.000 for episodic active phase and remission phase cluster headache patients, p = 0.103 for chronic cluster headache patients).
Preventive treatment
Five out of seven chronic cluster headache patients who reported attacks took preventive medication and four out of seven patients who did not report attacks took preventive medication.
Four out of nine active phase episodic cluster headache patients reported using preventive treatment at stable doses for at least one week before entering the study. Five active phase episodic cluster headache patients were not on any preventive treatment preceding or during the study.
Two of nine remission phase episodic cluster headache patients reported using preventive treatment at stable doses for at least one week before entering the study.
Patients with remission phase episodic cluster headache
Two patients (one male, one female) were excluded from final analysis due to coexisting migraine with and without aura. None of the patients developed cluster headache attacks on CGRP or placebo day.
Furthermore, none of the patients reported any migraine-like attacks on CGRP or placebo day.
Patients in active disease phase
As an exploratory analysis we pooled together patients in active disease phase; episodic cluster headache active phase and chronic cluster headache patients. Fifteen of 23 active phase patients developed a cluster-like attack after CGRP (mean 65%, 95% CI 44-86%) compared to one after placebo (mean 4%, 95% CI 0-13%) (P=0.001). Only one patient reported a cluster headache attack on placebo day. Thus, we did not conduct statistical tests on difference in time to peak headache intensity between experimental days.
Vital signs
CGRP increased heart rate compared to placebo in active phase episodic cluster headache (P=0.020), chronic cluster headache (P=0.002), and remission phase episodic cluster headache (P=0.003) patients. No difference in MAP was found between CGRP and placebo in active phase episodic cluster headache, chronic cluster headache, and remission phase episodic cluster headache patients (P>0.05).
